Journal of Leukemia & Lymphoma 2021;30(12):735-738

doi:10.3760/cma.j.cn115356-20210505-00107

Rituximab combined with ABVD regimen in treatment of Hodgkin lymphoma with autoimmune hemolytic anemia: report of one case and review of literature

Yan YAN 1 ; Xiaofei CHAI ; Jianwei DU ; Xue GAO ; Yufu LI ; Yongping SONG ; Quande LIN

Affiliations

+expand

Keywords

Lymphoma, Hodgkin; Anemia, hemolytic, autoimmune; Rituximab; Antineoplastic combined chemotherapy protocols

Country

China

Language

Chinese

Abstract

Objective:To explore the efficacy of rituximab combined with ABVD (epirubicin+ bleomycin+ vindesine +dacarbazine) regimen in treatment of Hodgkin lymphoma (HL) complicated with autoimmune hemolytic anemia (AIHA).Methods:The clinical data of 1 HL patient complicated with AIHA in November 2019 in Henan Cancer Hospital were retrospectively analyzed, and literatures were reviewed.Results:The patient received left cervical lymph node biopsy and bone marrow biopsy, and then lymphoma-related gene mutations and whole genetic genome detection were performed. The patient was diagnosed as HL (tuberous sclerosis in stage Ⅳ) complicated with AIHA. After 6 cycles of rituximab combined with ABVD regimen, the efficacy was evaluated. This patient's anemia was recovered, and HL also achieved complete remission.Conclusions:Rituximab combined with ABVD regimen is effective in treatment of HL patients complicated with AIHA.